PR Newswire
CAMBRIDGE, Mass. , May 22, 2024 /PRNewswire/ -- GV20 Therapeutics, a clinical-stage biotechnology company integrating AI, genomics, and disease biology to create next-generation antibody therapeutics for cancer, announced today that it will present at the Jefferies Global Healthcare Conference Private Biotech Day, taking place June 4th, 2024 , in New York .
Company management will be conducting one-on-one meetings with investors at the conference.
ABOUT GV20 THERAPEUTICS
At GV20 Therapeutics, our mission is to develop a differentiated pipeline of innovative antibody therapeutics to transform cancer treatment. We leverage our in-house STEAD platform (Simultaneous Target Evaluation and Antibody Discovery), which integrates AI, genomics, and disease biology to identify novel drug targets and create next-generation therapies against these targets. Our lead program, GV20-0251, is a first-in-class, fully human, Fc-attenuated IgG1 monoclonal antibody targeting a novel innate immune checkpoint IGSF8. The GV20-0251-100 multi-center Phase I clinical trial in patients with advanced solid tumors ( NCT05669430 ) is the first clinical study of an AI-designed antibody against an AI-predicted target. GV20 is headquartered in Cambridge, MA.
To learn more about GV20, please visit https://gv20tx.com/ and follow the company on LinkedIn.
Business Contact
Ying
Gong,
Ph.D
.,
CBO
BD@gv20tx.com
Investor and Media Contact
Amy Conrad
Juniper Point
amy@juniper-point.com
View original content: https://www.prnewswire.com/news-releases/gv20-therapeutics-to-present-at-the-jefferies-healthcare-conference-private-biotech-day-302152897.html
SOURCE GV20 Therapeutics